GlassScriptPhysician profile
Preeti Kallu
NPI 1164615829
$2,650.69
in general payments reported to CMS, 2019-2025
30 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $67.38 · 2021: $275 · 2022: $401 · 2023: $539 · 2024: $659 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.45 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $409.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $220.86 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $192.71 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.02 | 2019-2023 | Jardiance |
| Pfizer INC. | $143.61 | 2019-2024 | |
| Amgen INC. | $139.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $138.01 | 2019 | |
| Abbvie INC. | $122.43 | 2022-2025 | |
| Shield Therapeutics INC | $73.71 | 2023-2024 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $54.16 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $54.05 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $42.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.52 | 2019 | |
| Bardy Diagnostics, INC. | $30.00 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $26.85 | 2021-2024 | Contrave |
| Medline Industries LP | $25.70 | 2024 | |
| Ibsa Pharma INC. | $22.15 | 2024 | Tirosint, Licart |
| Horizon Therapeutics Plc | $20.90 | 2020 | |
| Linus Health, INC. | $20.67 | 2023 | |
| Beta Bionics, INC. | $19.74 | 2024 | Ilet Bionic Pancreas |
| Biohaven Pharmaceuticals, INC. | $19.56 | 2021 | |
| Dexcom, INC. | $18.92 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $18.02 | 2024 | Yupelri |
| Acella Pharmaceuticals, LLC | $17.91 | 2024 | NP Thyroid 60 |
| Nevro Corp. | $16.58 | 2024 | Senza |
| Novartis Pharmaceuticals Corporation | $15.87 | 2022 | |
| Allergan, INC. | $13.62 | 2019 | |
| Eisai INC. | $13.47 | 2021 | |
| Boston Scientific Corporation | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preeti Kallu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.